Focused ultrasound plus nivolumab for children with brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 25 years old.
- You must have a brain tumor that has come back or gotten worse after previous treatment.
- You should be able to walk and care for yourself most of the day (Lansky or Karnofsky score of 60 or higher).
- You must have had at least one prior treatment for your tumor.
- You must wait at least 4 weeks after radiation, immunotherapy, or antibody therapy before starting this trial.
- You must have stable blood counts and organ function as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a combination of focused ultrasound and the immunotherapy drug pembrolizumab for people whose glioblastoma has returned after standard treatment. The ultrasound may help the drug work better by temporarily opening the blood-brain barrier.
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
This trial tests a device that uses focused ultrasound to help the drug bevacizumab (Avastin) better reach brain tumor cells. It is for people with glioblastoma that has come back after standard treatments like radiation and temozolomide.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.